Cargando…

Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study

PURPOSE: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. MATERIALS AND METHODS: We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB sympt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shim, Myungsun, Kim, Jong Keun, Bang, Woo Jin, Lee, Yong Seong, Cho, Sung Tae, Cho, Jin Seon, Joo, Kwan Joong, Hyun, Jae Seog, Kim, Byung Hoon, Lee, Jong Bok, Seo, Young Jin, Oh, Cheol Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606123/ https://www.ncbi.nlm.nih.gov/pubmed/32985146 http://dx.doi.org/10.4111/icu.20200053

Ejemplares similares

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
por: Jo, Sunmi, et al.
Publicado: (2016)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
por: Shin, Jung Hyun, et al.
Publicado: (2017)

A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3
por: Park, Young-Chul, et al.
Publicado: (2019)

Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome
por: Xia, Liping, et al.
Publicado: (2021)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
por: Hsiao, Sheng-Mou, et al.
Publicado: (2015)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
por: Shim, Myungsun, et al.
Publicado: (2022)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
por: Bang, Woo Jin, et al.
Publicado: (2022)

Effect of Diabetes Mellitus on Symptomatic Improvement After Surgery for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptom and its Relations With Prostatic Urethral Angulation
por: Jo, Jung Ki, et al.
Publicado: (2023)

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
por: Han, Seok-Hee, et al.
Publicado: (2019)

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis
por: Xu, Rui, et al.
Publicado: (2022)

Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial
por: Shim, Myungsun, et al.
Publicado: (2021)

Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial
por: Jin, Cai-De, et al.
Publicado: (2021)

Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2015)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
por: Kim, Su Jin, et al.
Publicado: (2017)

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

Efficacy and Tolerability of Anticholinergics in Korean Children with Overactive Bladder: A Multicenter Retrospective Study
por: Park, Se Jin, et al.
Publicado: (2014)

Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women
por: Shim, Jae-Yoon, et al.
Publicado: (2018)

Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension
por: Sung, Ki‐Chul, et al.
Publicado: (2023)

Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
por: Cho, Yeona, et al.
Publicado: (2020)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3mb3vjom7mltt96rmp6qo4soel